Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21684959 | 1.00 | F10 (0.36) | F10MAP4K1TYMSMEN1KMT2A | |
| SCHEMBL21685676 | 0.73 | MAP4K1 (0.40) | MAP4K1MEN1KMT2ACHEK1ELANE | |
| SCHEMBL21703328 | 0.73 | MAP4K1 (0.55) | MAP4K1CHEK1ELANEKCNH2 | |
| SCHEMBL21685623 | 0.73 | MAP4K1 (0.56) | MAP4K1 | |
| SCHEMBL21685451 | 0.73 | DRD4 (0.40) | F10MAP4K1TYMSMEN1KMT2A | |
| SCHEMBL23453061 | 0.72 | MAP4K1 (0.39) | MAP4K1MEN1KMT2ACHEK1ELANE | |
| SCHEMBL21703330 | 0.71 | MAP4K1 (0.43) | MAP4K1KCNH2PTGER3 | |
| SCHEMBL23453060 | 0.71 | MAP4K1 (0.38) | MAP4K1MEN1KMT2ACHEK1ELANE | |
| SCHEMBL21685318 | 0.70 | F10 (0.37) | F10 | |
| SCHEMBL21684855 | 0.70 | CHEK1 (0.42) | MAP4K1CHEK1ELANEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | F10 1686/4885MAP4K1 2520/4885TYMS 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.